ClinicalTrials.gg
Active, not recruitingNCT04179032Updated Aug 19, 2026Results posted

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Active, not recruiting at 11 sites in 7 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
29th of 36
25 · median 81
Started
2019
the only one that year
Phase 2
8 of 36
2 open now
Registered
25th of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 29th largest by enrollment, is the only one that started in 2019, is one of 8 in phase 2, and was the 25th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to 17 years of age with SLE on a background of standard of care therapy. This bridging PK study is part of an extrapolation strategy to support the use of SC belimumab in pediatric SLE participants, based on the completed adult SLE study with SC belimumab and the pediatric SLE study with intravenous (IV) belimumab. Part A is an open label 12-week treatment phase where participants will be enrolled and allocated to treatment cohorts based on their body weight at baseline. The dose and dosing regimens selected for SC administration in this pediatric population are intended to achieve a similar average exposure as observed with the weekly 200 mg SC dosing regimen in adult SLE patients. Part B is an optional 40-week open-label continuation phase, open to all participants who have completed Part A. Dosing of SC belimumab may continue at the same frequency in Part B or may require a change in frequency according to changes in participant body weight. The total duration of the study will be 68 weeks including a 12-Week open label treatment phase (Part A), an optional 40-week open-label continuation phase (Part B) and 16-week follow-up.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Belimumab
  • Pediatric
  • Pharmacokinetics
  • Pharmacodynamics
  • Safety
  • Systemic lupus erythematosus
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be between 5 and 17 years of age inclusive, at the time of Day 1.
  • Participants who meet the 1997 American College of Rheumatology (ACR) criteria for the classification of SLE;

    • Have or have had in series 4 or more of the 11 ACR criteria for the classification of SLE.
  • Have active SLE disease defined as a safety of estrogen in lupus erythematosus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score >=6 at screening.
  • Have documented positive autoantibody test results within the study screening period, defined as an anti-nuclear antibody (ANA) titre >= 1:80 and/or a positive anti-dsDNA (>=30 international units per milliliter [IU/mL]) serum antibody test based on either the study's central laboratory results or the local laboratory results. Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted
  • Are on a stable SLE treatment regimen, "Stable treatment at Baseline" consists of any of the following medications (alone or in combination) administered for a period of at least 30 days prior to Day 1;

    • [prednisone or prednisone equivalent up to 0.5 milligram per kilogram per day (mg/kg/day)], for those participants on alternating day doses of steroids, use the average of 2 daily doses to calculate the average daily steroid dose.
    • Other or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), calcineurin inhibitors (e.g. tacrolimus, cyclosporine), sirolimus, oral cyclophosphamide, 6-mercaptopurine or thalidomide.
    • Anti-malarials (e.g. hydroxychloroquine, chloroquine, quinacrine).
    • Non-steroidal anti-inflammatory drugs (NSAIDs)
    • New SLE therapy must not be added within 30 days of Day 1.
  • Body weight >=15 kg.
  • Male and/or female;

    • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • No contraceptive measures are required for male participants.
    • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies, Is not a woman of (WOCBP) or Is a WOCBP and is using a contraceptive method that is highly effective, with a failure rate of \<1%, during the belimumab treatment period and for at least 16 weeks, corresponding to the time needed to eliminate any study intervention(s) (e.g., 5 terminal half-lives), after the last dose of study intervention. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
    • A WOCBP must have a negative highly sensitive pregnancy test (serum or as required by local regulations) within 35 days before the first dose of belimumab.
    • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Participant signs and dates a written age appropriate assent form (in accordance with applicable regulations) and the parent or legal guardian (or emancipated minor) that has the ability to understand the requirements of the study, provides written (including consent for the use and disclosure of research-related health information) that the participant will comply with the study protocol procedures (including required study visits).

Exclusion criteria

Exclusion Criteria:

  • Have an estimated (eGFR) as calculated by Schwartz Formula of less than 30 milliliter/minute (mL/min).
  • Have acute severe nephritis defined as significant renal disease (e.g., the presence of urinary sediments and other laboratory abnormalities) that, in the opinion of the study investigator, may lead to the participant requiring induction therapy during the first 12 weeks of the trial.
  • Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoetic stem cell/marrow transplant.
  • Have clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.
  • Have a planned surgical procedure or a history of any other medical disease (e.g., cardiopulmonary), laboratory abnormality, or condition (e.g., poor venous access) that, in the opinion of the investigator, makes the participant unsuitable for the study.
  • Have a history of malignant neoplasm within the last 5 years.
  • Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months, or who in the investigator's opinion, pose a significant suicide risk.
  • Have a history of a primary immunodeficiency.
  • Have an immunoglobulin A (IgA) deficiency (IgA level \<10 milligrams per deciliter [mg/dL]).
  • Have acute or chronic infections requiring management, as follows;

    • Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria).
    • Use of parenteral [IV or Intramuscular (IM)] antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) for infection within 60 days of Day 1.
  • Have a Grade 3 or greater laboratory abnormality based on the protocol defined adverse event and laboratory value severity grade scale except for the following that are allowed;

    • Stable Grade 3 (PT) secondary to warfarin treatment.
    • Stable Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.
    • Stable Grade 3 hypoalbuminemia due to lupus nephritis, and not related to liver disease or malnutrition.
    • Any grade proteinuria.
    • Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes or viral hepatitis. If present, any abnormalities in the alanine amininotransferase () and or aspartate aminotransferase (AST) must be \<= Grade 2.
    • Stable Grade 3 neutropenia; or stable Grade 3 lymphopenia; or stable Grade 3 leukopenia, due to SLE.
  • Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
  • Have ever received treatment with belimumab.
  • Have received any of the following within 364 days of Day 1;

    • Treatment with any B-cell targeted therapy [e.g., rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], B lymphocyte stimulator (BLyS)-receptor fusion protein [BR3], transmembrane activator attached to the Fc portion of an immunoglobulin [TACI Fc]).
    • Abatacept.
    • Any biologic agent.
  • Have required 3 or more courses of systemic for concomitant conditions (e.g., asthma, atopic dermatitis) within 90 days of Day 1 (topical or inhaled steroids are permitted).
  • Have received any of the following within 90 days of Day 1;

    • Anti-tumor necrosis factor (TNF) therapy (e.g., adalimumab, etanercept, infliximab).
    • Interleukin-1 receptor antagonist (anakinra).
    • Intravenous immunoglobulin (IVIG).
    • Plasmapheresis.
  • Have received any of the following within 30 days of Day 1;

    • IV cyclophosphamide.
    • A non-biologic investigational agent (30 day window or 5 half-lives, whichever is greater).
    • Any new /immunomodulatory agent.
    • High dose prednisone or equivalent (>1.5 mg/kg/day) or any intramuscular or intravenous steroid injection.
  • Have received a live or within 30 days of Day 1.
  • Have active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS vasculitis) requiring therapeutic intervention within 60 days of Day 1.
  • Have required renal replacement therapy (e.g. hemodialysis, peritoneal dialysis) within 90 days of Day 1 or are currently on renal replacement therapy.
  • Participation in an interventional clinical study either concurrently or within 6 months of screening. Participation in an observational study may be permitted.
  • Positive immunodeficiency virus () antibody test
  • : Serologic evidence of Hepatitis B (HB) infection defined as Hepatitis B surface antigen positive (HBsAg+) or Hepatitis B core antibody positive (HBcAb+)
  • : Positive test for Hepatitis C antibody confirmed on an additional blood sample by ribonucleic acid (RNA) polymerase chain reaction (PCR) assay. Participants who are positive for Hepatitis C antibody and negative when the Hepatitis C RNA-PCR assay is performed on an additional sample will be eligible to participate. Participants who are positive for Hepatitis C antibody and have a positive result for the Hepatitis C virus (HCV) when the Hepatitis C RNA PCR assay is performed on the additional sample will not be eligible to participate. (Institution or country specific guidelines for blood sample volume limits must be followed in collection of the additional blood sample).
  • Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 1.
  • Are unable or unlikely, in the opinion of the investigator, to administer belimumab by SC injection and have no reliable source to administer the injection
  • Children in Care: A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a CiC can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The determination of whether a child meets the definition of CiC should be made with the study centre staff in consultation with the responsible institutional review board (IRB)/Ethics Committee.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Belimumab 200 mg

    Participants with Systemic Lupus Erythematosus were administered with Belimumab 200 milligram per milliliter (mg/mL) subcutaneous (SC) injection. The dosing frequency was based on body weight. Participants who weigh more than or equal to 50 kilograms were administered every week, who weigh between 30 to less than 50 kg were administered every 10 days and who weigh less than 30 kg were administered every 2 weeks.

    Combination Product: Belimumab

Interventions

  • Combination productBelimumab

    Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.

06

What researchers measure

Primary outcomes

  1. Observed Belimumab Concentrations at Week 12

    Blood samples were collected for measurement of serum concentrations of belimumab. Observed belimumab concentrations at Week 12 is presented.

    Time frame: At Week 12

  2. Estimated Average Concentration (Cavg) of Belimumab at Steady State

    Blood samples were collected for measurement of serum concentrations of belimumab at steady state. Average concentrations were analyzed and reported for all time-points from Week 1 through Week 60.

    Time frame: Pre dose on Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52, and Week 60

  3. Estimated Maximum Concentration (Cmax) of Belimumab at Steady State

    Blood samples were collected for measurement of serum concentrations of belimumab at steady state. Cmax was analyzed and reported for all time-points from Week 1 through Week 60.

    Time frame: Pre dose on Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52, and Week 60

  4. Estimated Minimum Concentration (Cmin) of Belimumab at Steady State

    Blood samples were collected for measurement of serum concentrations of belimumab at steady state. Cmin was analyzed and reported for all time-points from Week 1 through Week 60.

    Time frame: Pre dose on Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52, and Week 60

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 68

  2. Number of Participants With Serious Adverse Events (SAEs)

    A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.

    Time frame: Up to Week 68

  3. Number of Participants With Adverse Events of Special Interest (AESIs)

    AESI included post-injection systemic reactions and hypersensitivity reactions, infections, malignancies, and depression/suicidality/self-injury. AESIs were followed until the event is resolved, stabilized, otherwise explained, or the participant is lost to follow-up.

    Time frame: Up to Week 68

  4. Percent Change From Baseline in Complement C3 and Complement C4 at Week 12 and Week 52

    Blood samples were collected from participants to assess complement C3 and complement C4 levels. Baseline status are defined as low complement \[C3 less than (\<) 90 milligrams per deciliter (mg/dL)\] or normal/high (C3 \>= 90 mg/dL) and low (C4 \< 13 mg/dL) or normal/high (C4 \>= 13 mg/dL) respectively. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

    Time frame: Baseline (Day 1), Week 12 and Week 52

  5. Percent Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (dsDNA) Antibodies at Week 12 and Week 52

    Blood samples were collected for anti-dsDNA- antibody biomarker analysis. Baseline status are defined as positive (Anti-dsDNA antibody \>= 30 International Units Per Milliliter (IU/mL)) or negative (Anti-dsDNA antibody\< 30 IU/mL). Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

    Time frame: Baseline (Day 1), Week 12 and Week 52

  6. Percent Change From Baseline in CD19+ Total B Cells and CD20+ B Cells at Week 12 and Week 52

    Blood samples were collected for biomarker analysis. B cell subsets included CD19+ total B cells and CD 20+ B cells. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

    Time frame: Baseline (Day 1), Week 12 and Week 52

  7. Percent Change From Baseline in Naïve B Cells and Memory B Cells at Week 12 and Week 52

    Blood samples were collected for biomarker analysis and included CD20+ CD27- Naïve B cells and CD20+ CD27+ memory B cell. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

    Time frame: Baseline (Day 1), Week 12 and Week 52

  8. Percent Change From Baseline in in CD27bright CD38bright Plasma Blasts at Week 12 and Week 52

    Blood samples were collected for CD27bright CD38bright Plasma blasts biomarker analysis. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

    Time frame: Baseline (Day 1), Week 12 and Week 52

  9. Percent Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 12

    Blood samples were collected for analysis of immunoglobulins: Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM). Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 divided by the Baseline value X 100.

    Time frame: Baseline (Day 1) and Week 12

  10. Percent Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 52

    Blood samples were collected for analysis of immunoglobulins: Immunoglobulin A (IgA), Immunoglobulin A (IgG), and Immunoglobulin M (IgM). Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100.

    Time frame: Baseline (Day 1) and Week 52

07

Results

Posted Mar 26, 2024

Participant flow

A total of 28 participants were screened and 25 were enrolled to the study. The primary study included Part A which is an open label 12-week treatment phase and Part B an optional 40-week open-label continuation phase, open to all participants who have completed Part A. An optional access extension phase is ongoing.

Part A (Up to Week 12)
Participant flow — Part A (Up to Week 12)
MilestoneBelimumab 200 mg
Started25
Completed25
Not completed0
Part B (Up to Week 52)
Participant flow — Part B (Up to Week 52)
MilestoneBelimumab 200 mg
Started25
Completed23
Not completed2
Withdrew: Adverse event1
Withdrew: Investigator discretion1
Access Extension Phase
Participant flow — Access Extension Phase
MilestoneBelimumab 200 mg
Started11
Completed0
Not completed11
Withdrew: Ongoing11

Outcome measures

PrimaryObserved Belimumab Concentrations at Week 12

Blood samples were collected for measurement of serum concentrations of belimumab. Observed belimumab concentrations at Week 12 is presented.

Time frame:
At Week 12
Reported as:
Geometric mean · microgram per milliliter (ug/ml)
Observed Belimumab Concentrations at Week 12
microgram per milliliter (ug/ml)Belimumab 200 mg
Observed Belimumab Concentrations at Week 12106.42 (87.80 to 128.99)
PrimaryEstimated Average Concentration (Cavg) of Belimumab at Steady State

Blood samples were collected for measurement of serum concentrations of belimumab at steady state. Average concentrations were analyzed and reported for all time-points from Week 1 through Week 60.

Time frame:
Pre dose on Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52, and Week 60
Reported as:
Geometric mean · ug/ml
Estimated Average Concentration (Cavg) of Belimumab at Steady State
ug/mlBelimumab 200 mg
Estimated Average Concentration (Cavg) of Belimumab at Steady State124 ± 37.3
PrimaryEstimated Maximum Concentration (Cmax) of Belimumab at Steady State

Blood samples were collected for measurement of serum concentrations of belimumab at steady state. Cmax was analyzed and reported for all time-points from Week 1 through Week 60.

Time frame:
Pre dose on Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52, and Week 60
Reported as:
Geometric mean · ug/ml
Estimated Maximum Concentration (Cmax) of Belimumab at Steady State
ug/mlBelimumab 200 mg
Estimated Maximum Concentration (Cmax) of Belimumab at Steady State131 ± 34.9
PrimaryEstimated Minimum Concentration (Cmin) of Belimumab at Steady State

Blood samples were collected for measurement of serum concentrations of belimumab at steady state. Cmin was analyzed and reported for all time-points from Week 1 through Week 60.

Time frame:
Pre dose on Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52, and Week 60
Reported as:
Geometric mean · ug/ml
Estimated Minimum Concentration (Cmin) of Belimumab at Steady State
ug/mlBelimumab 200 mg
Estimated Minimum Concentration (Cmin) of Belimumab at Steady State112 ± 41.7
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Week 68
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsBelimumab 200 mg
Number of Participants With Adverse Events (AEs)22
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.

Time frame:
Up to Week 68
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsBelimumab 200 mg
Number of Participants With Serious Adverse Events (SAEs)1
SecondaryNumber of Participants With Adverse Events of Special Interest (AESIs)

AESI included post-injection systemic reactions and hypersensitivity reactions, infections, malignancies, and depression/suicidality/self-injury. AESIs were followed until the event is resolved, stabilized, otherwise explained, or the participant is lost to follow-up.

Time frame:
Up to Week 68
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsBelimumab 200 mg
Malignancies0
Post-Injection Systemic Reactions3
Infections0
Depression/Suicide/Self-injury0
SecondaryPercent Change From Baseline in Complement C3 and Complement C4 at Week 12 and Week 52

Blood samples were collected from participants to assess complement C3 and complement C4 levels. Baseline status are defined as low complement \[C3 less than (\<) 90 milligrams per deciliter (mg/dL)\] or normal/high (C3 \>= 90 mg/dL) and low (C4 \< 13 mg/dL) or normal/high (C4 \>= 13 mg/dL) respectively. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

Time frame:
Baseline (Day 1), Week 12 and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in Complement C3 and Complement C4 at Week 12 and Week 52
Percent changeBelimumab 200 mg
Complement C3 (Week 12)8.26 (2.0 to 24.8)
Complement C3 (Week 52)23.46 (-7.6 to 61.6)
Complement C4 (Week 12)31.03 (-3.5 to 67.3)
Complement C4 (Week 52)67.52 (21.8 to 443.2)
SecondaryPercent Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (dsDNA) Antibodies at Week 12 and Week 52

Blood samples were collected for anti-dsDNA- antibody biomarker analysis. Baseline status are defined as positive (Anti-dsDNA antibody \>= 30 International Units Per Milliliter (IU/mL)) or negative (Anti-dsDNA antibody\< 30 IU/mL). Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

Time frame:
Baseline (Day 1), Week 12 and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (dsDNA) Antibodies at Week 12 and Week 52
Percent changeBelimumab 200 mg
Week 12-17.74 (-68.0 to 40.0)
Week 52-58.88 (-85.3 to -2.4)
SecondaryPercent Change From Baseline in CD19+ Total B Cells and CD20+ B Cells at Week 12 and Week 52

Blood samples were collected for biomarker analysis. B cell subsets included CD19+ total B cells and CD 20+ B cells. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

Time frame:
Baseline (Day 1), Week 12 and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in CD19+ Total B Cells and CD20+ B Cells at Week 12 and Week 52
Percent changeBelimumab 200 mg
CD19+ Total B cells (Week 12)-42.97 (-74.4 to 68.8)
CD19+ Total B cells (Week 52)-61.32 (-89.4 to 95.5)
CD20+ B cells (Week 12)-41.85 (-75.8 to 92.1)
CD20+ B cells (Week 52)-61.65 (-89.9 to 92.3)
SecondaryPercent Change From Baseline in Naïve B Cells and Memory B Cells at Week 12 and Week 52

Blood samples were collected for biomarker analysis and included CD20+ CD27- Naïve B cells and CD20+ CD27+ memory B cell. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

Time frame:
Baseline (Day 1), Week 12 and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in Naïve B Cells and Memory B Cells at Week 12 and Week 52
Percent changeBelimumab 200 mg
Naïve B Cells (Week 12)-53.19 (-81.5 to 21.0)
Naïve B Cells (Week 52)-72.13 (-94.5 to 20.3)
Memory B Cells (Week 12)69.06 (-36.7 to 531.8)
Memory B Cells (Week 52)27.10 (-63.2 to 402.9)
SecondaryPercent Change From Baseline in in CD27bright CD38bright Plasma Blasts at Week 12 and Week 52

Blood samples were collected for CD27bright CD38bright Plasma blasts biomarker analysis. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 and 52 divided by the Baseline value X 100.

Time frame:
Baseline (Day 1), Week 12 and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in in CD27bright CD38bright Plasma Blasts at Week 12 and Week 52
Percent changeBelimumab 200 mg
Week 129.40 (-81.8 to 428.1)
Week 52-70.07 (-88.9 to 193.1)
SecondaryPercent Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 12

Blood samples were collected for analysis of immunoglobulins: Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM). Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 12 divided by the Baseline value X 100.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Median · Percent change
Percent Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 12
Percent changeBelimumab 200 mg
Immunoglobulin A (IgA)-3.13 (-35.2 to 8.0)
Immunoglobulin G (IgG)-3.40 (-30.7 to 12.7)
Immunoglobulin M (IgM)-10.41 (-49.2 to 4.3)
SecondaryPercent Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 52

Blood samples were collected for analysis of immunoglobulins: Immunoglobulin A (IgA), Immunoglobulin A (IgG), and Immunoglobulin M (IgM). Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 52
Percent changeBelimumab 200 mg
Immunoglobulin A (IgA)-13.06 (-37.5 to 41.0)
Immunoglobulin G (IgG)-12.29 (-34.0 to 10.6)
Immunoglobulin M (IgM)-30.79 (-56.7 to -8.9)

Adverse events

Collected over Up to Week 68 (treatment: up to 52 weeks [12 weeks Part A; 40 weeks Part B extension phase] and follow-up: 16 weeks). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab 200 mg0/25 (0%)1/25 (4%)19/25 (76%)
Most frequent serious events
Most frequent serious events
EventBelimumab 200 mg
COVID-19Infections and infestations1/25
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBelimumab 200 mg
COVID-19Infections and infestations8/25
LeukopeniaBlood and lymphatic system disorders4/25
NeutropeniaBlood and lymphatic system disorders4/25
Injection site painGeneral disorders4/25
LymphopeniaBlood and lymphatic system disorders3/25
NasopharyngitisInfections and infestations3/25
Upper respiratory tract infectionInfections and infestations3/25
AnaemiaBlood and lymphatic system disorders2/25
Injection site erythemaGeneral disorders2/25
Viral infectionInfections and infestations2/25

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Belimumab 200 mg
Mean14.0 ± 2.09
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab 200 mg
Female21
Male4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab 200 mg
AMERICAN INDIAN OR ALASKA NATIVE3
ASIAN4
BLACK OR AFRICAN AMERICAN1
WHITE16
MIXED RACE1
08

Study locations

11 sites
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Rosario, 2000, Argentina
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Saint Augustin, 53757, Germany
  • GSK Investigational Site
    Kagoshima, 890-8520, Japan
  • GSK Investigational Site
    Kanagawa, 216-8511, Japan
  • GSK Investigational Site
    San Luis Potosí City, 78213, Mexico
  • GSK Investigational Site
    Rotterdam, 3015 GJ, Netherlands
  • GSK Investigational Site
    Barcelona, 08950, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
09

References and documents

Publications

  • Brunner HI, Anton J, Calvo-Penades I, Dimelow R, Horneff G, Kamphuis S, Marino R, van Maurik A, Minden K, Mori M, Ocran-Appiah J, Wilkinson C, Yamasaki Y, Assudani D; Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators. Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial. Arthritis Care Res (Hoboken). 2026 Jun;78(6):761-770. doi: 10.1002/acr.25700. Epub 2026 Feb 10. PubMed 41261055 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2023, 37 months.

Results were first posted in Mar 2024, 1 year 2 months after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 37 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 26, 2019
StartActual
Nov 28, 2019
Primary completionActual
Jan 16, 2023
CompletionEst.
Sep 30, 2027
Results first posted
Mar 26, 2024
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04179032
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 26, 2019
Start date
Nov 28, 2019
Primary completion
Jan 16, 2023
Completion
Sep 30, 2027 (estimated)
Results posted
Mar 26, 2024
Last update
Aug 19, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion